Stock listing

Innoviva, Inc.

Selected listing: A2AC9U · LS · EUR · DE

Innoviva, Inc. (Lang & Schwarz: A2AC9U), Health Technology. Latest release Aug 12, 2026: Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO(R)…

A2AC9U:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2AC9U
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Innoviva, Inc.

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO(R), ZEVTERA(R) and NUZOLVENCE(R) Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

August 12, 2026

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

August 11, 2026

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

August 5, 2026

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

June 16, 2026

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

May 6, 2026

All Innoviva, Inc. news →

Research Innoviva, Inc.

Innoviva, Inc. company profile

View the public company page for Innoviva, Inc. on 6ix.

Innoviva, Inc. news

Read company news and market updates connected to Innoviva, Inc..

Innoviva, Inc. investor events

Find investor webinars, events, and replay context for Innoviva, Inc..